TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05407337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy using Narrative Exposure Therapy (NET)
Description: There are four NET sessions, each lasting thirty minutes and defined in advance on a weekly basis. The first session is the one where the person concerned will establish his/her Life Line and start his/her life story with the peer mediator.~The second and third session will be the one where the person will continue his life story. Each session will begin with the mediator reading the story from the previous session, with the person concerned modifying the story if they wish.~The fourth session will also start with the reading of the story from the previous session and will finish the story if necessary. It will also be the occasion to give the printed story to the person concerned at the end of the session and have it signed by the mediator and the patient.~To prevent a possible risk of decompensation of the subject during the session, there will be a psychiatrist on site at the time of the NET to be available if the patient needs it.
Study: NCT06527573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active repetitive transcranial magnetic stimulation
Description: During the rTMS-active stage, treatment will be given for 7 consecutive days (two session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active repetitive transcranial magnetic stimulation
Description: During the rTMS-active stage, treatment will be given for 7 consecutive days (two session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation
Description: The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.(train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 0 pulses at 90% of RMT).
Study: NCT06184698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 5 mg/kg
Study: NCT05442580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3x10(6) CART-38 cellls
Description: 3x10(6) CART-38 cells via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3x10(6) CART-38 cellls
Description: 3x10(6) CART-38 cells via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7x10(5) CART-38 cells
Description: 7x10(5) CART-38 cells via intravenous infusion
Study: NCT05814263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIS/LBB pacing
Description: 3830 lead to HIS or LBB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LV pacing
Description: LV lead in a CS branch
Study: NCT05164770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
Description: Zanubrutinib+R-CHOP Regimen: Zanubrutinib 160mg bid; R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-DA-EPOCH Regimen: Zanubrutinib 160mg bid; R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-HD MTX Regimen: Zanubrutinib 160mg bid; R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP; R-DA-EPOCH; R-HD MTX
Description: R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg/m2 d1, Doxorubicin 50mg/m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg/m2 or Vindesine 3mg/m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/m2, Epirubicin 15mg/m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.
Study: NCT05244057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide
Description: 6.3mg, s.c., qd for 48 weeks
Study: NCT05442580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7x10(5) CART-38 cells
Description: 7x10(5) CART-38 cells via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7x10(6) CART-38 cells
Description: 7x10(6) CART-38 cells via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7x10(6) CART-38 cells
Description: 7x10(6) CART-38 cells via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3x10(7) CART-38 cells
Description: 3x10(7) CART-38 cells via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3x10(7) CART-38 cells
Description: 3x10(7) CART-38 cells via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy administered at physician discretion
Study: NCT04711122

Intervention type: DRUG
Intervention: Third generation cephalosporin antibiotics
Description: Assessment of antibiotic effect
Study: NCT06154915

Intervention type: OTHER
Intervention: medical treatments
Description: All patients will follow the medical treatments, as recommended by the multidisciplinary clinical team (for example revascularization or ulcer debriding) according to the best standard of care

Intervention type: OTHER
Intervention: medical treatments
Description: All patients will follow the medical treatments, as recommended by the multidisciplinary clinical team (for example revascularization or ulcer debriding) according to the best standard of care
Study: NCT05706428

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NHFOV
Description: The neonate patients with respiratory distress will have nasal high frequency ventilation as an initial mode of respiratory support.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NCPAP
Description: The neonate patients with respiratory distress will have nasal continuous positive airway pressure as an initial mode of respiratory support.
Study: NCT06542276

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermal Vectored Pulsation
Description: The LipiFlow® (Johnson \& Johnson Vision, USA) Thermal Pulsation System, also known as vectored thermal pulsation, is a treatment that applies localized heat and pressure to the meibomian glands lining the eyelids. The device consists of a console connected to single-use, sterile devices applied to each eye known as activators. The activator includes an eye warmer with a large lens that gently sits on the conjunctiva of each eye. The activator cups the upper and lower eyelid and applies regulated, outward heat to the surface of the palpebral conjunctiva with an air bladder that intermittently provides directional, controlled massage of the eyelids to promote expression of the liquified contents.
Study: NCT06540300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rTMS stimulation of right IPL
Description: The stimulation site is the right IPL (EEG International 10-20 system, electrode CP4/CP6), with a stimulation frequency of 1-Hz and intensity of 100% RMT. There are 50 pulses each time, 20 seconds each cycle, 5 seconds each, with an interval of 15 seconds, for a total of 60 cycles, a total duration of 20 minutes, and a total of 3000 pulses. Perform treatment once a day, rest for 2 days after 5 consecutive days of treatment, for a total of 2 weeks, and receive 10 treatments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rTMS stimulation of right IPL
Description: The stimulation site is the right IPL (EEG International 10-20 system, electrode CP4/CP6), with a stimulation frequency of 1-Hz and intensity of 100% RMT. There are 50 pulses each time, 20 seconds each cycle, 5 seconds each, with an interval of 15 seconds, for a total of 60 cycles, a total duration of 20 minutes, and a total of 3000 pulses. Perform treatment once a day, rest for 2 days after 5 consecutive days of treatment, for a total of 2 weeks, and receive 10 treatments.
Study: NCT05053919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Schumann resonance sleep device
Description: A Schumann resonance sleep device would stably output the composite frequency of a the Schumann resonance frequency (7.83 Hz) wave, theta wave, and delta wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sleep device
Description: A Placebo sleep device is an instrument with the same appearance and operation as the Schumann resonance sleep device, but does not output any frequency wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks.
Study: NCT05186922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06339021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Description: OCT-guided PCI based on MLD MAX algorithm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Description: OCT-guided PCI based on MLD MAX algorithm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional angiography-based PCI
Description: Conventional angiography-based PCI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional angiography-based PCI
Description: Conventional angiography-based PCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT de-escalation
Description: Aspirin and clopidogrel 30 days after DES implantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT de-escalation
Description: Aspirin and clopidogrel 30 days after DES implantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: default DAPT regimen
Description: Aspirin and ticagrelor 30 days after DES implantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: default DAPT regimen
Description: Aspirin and ticagrelor 30 days after DES implantation
Study: NCT05442580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy administered at physician discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy administered at physician discretion
Study: NCT06308913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB081776
Description: INCB081776 will be given orally on a daily basis. The highest safe/tolerable dose and schedule will be established by the ongoing phase 1 clinical trial of INCB081776 plus INCBMGA00012 (NCT03522142), which is 120 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint blockade with anti-PD-1 (Pembrolizumab) will be given as 200 mg IV on cycle 1 day 15 and cycle 1 day 36. Starting from cycle 2, pembrolizumab will be given on day 1 on each subsequent cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative RT
Description: Palliative RT will be given as either 24 Gy in 3 fractions (8 Gy per fraction) or 20 Gy in 5 fractions (4 Gy per fraction). The palliative radiation therapy dose will be determined based on the clinical judgment of the treating radiation oncology physician. Palliative RT must be completed between cycle 1 day 29 to cycle 1 day 33. After completion of palliative radiation therapy, patients will continue with additional cycles of INCB081776 and pembrolizumab until disease progression, intolerance to the combination regimen, or patient withdrawal.
Study: NCT06568302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as SC injection.
Study: NCT04853004

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV2 antibody measurement
Description: Blood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.
Study: NCT06204432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Citrate
Description: Those randomized to the Sodium Citrate arm will use 1 mL of 2.5% sodium citrate (3.5g/140 mL, pH 7.4, 298 mOsmol/L), 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Those randomized to the Normal Saline arm will use 1 mL of normal saline, 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olfactory Training Kit - The Olfactory Kit, by AdvancedRx
Description: All participants, regardless of study arm they are randomized to, will participate in olfactory training twice a day after use of their nasal spray

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory Training Kit - The Olfactory Kit, by AdvancedRx
Description: All participants, regardless of study arm they are randomized to, will participate in olfactory training twice a day after use of their nasal spray
Study: NCT05675384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS Active Treatment
Description: Using a 7-day/week wearable TENS device controlled by a Smart Phone App combined with moderate intensity lifestyle therapy,

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Using the sham (control) device combined with a moderate intensity lifestyle follow-up
Study: NCT05110950

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No suction EBUS-TBNA
Description: The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Passive suction through dedicated EBUS-TBNA syringe
Description: The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual applied suction EBUS-TBNA through a pistol-grip syringe holder
Description: The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs..
Study: NCT05244057

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Hepalatide
Description: s.c., qd for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide Tablets
Description: 25mg, p.o., qd for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir Alafenamide Tablets
Description: 25mg, p.o., qd for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alfa 2a
Description: 90ug, s.c., qw for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon alfa 2a
Description: 90ug, s.c., qw for 48 weeks
Study: NCT05984199

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCAR33
Description: Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCAR33
Description: Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCAR33
Description: Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCAR33
Description: Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCAR33
Description: Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCAR33
Description: Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy
Study: NCT06328647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POC Quantra QPlus System
Description: The POC Quantra QPlus System will be located in the operating room. Samples will be processed by trained (certified for POC testing) personnel and interpreted by the primary anesthesia team. The anesthesia team will perform a baseline hemostatic assessment , approximately 15 min prior to separation from CPB, and again 10-20 min following protamine administration using the Quantra POC hemostasis monitor. If persistent bleeding occurs despite clinical management, coagulation will be rechecked by a repeated Quantra assessment and treated as necessary. A Quantra device will be placed in the ICU for assessment for the first 6 hours following surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Blood and blood component transfusions will be determined by provider preference based on clinical findings. The anesthesia caregiver will perform laboratory testing for coagulation management at his/her discretion. Usual laboratory testing may include assessment of TEG with heparinase, platelet count, fibrinogen concentration at approximately 30-40 min prior to separation from cardiopulmonary bypass. Another set of laboratory tests may be sent post-CPB including TEG, platelet count, fibrinogen concentration, PT/aPTT, INR. Anesthesia caregiver will treat clinical bleeding and coagulopathy at his/her discretion.
Study: NCT04973137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birtamimab
Description: Intravenous administration of 24 mg/kg birtamimab every 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous 0.9% Saline administration as a placebo every 28 days
Study: NCT06327321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Volunteer without treatment
Description: Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.